1. Learning Objectives
Describe applicable results of important histology-specific clinical trials and put into clinical context
Identify investigational therapeutic regimens that would be alternatives to standard of care approaches
Evaluate current clinical practice approaches and applications to each specific patient and suggest alternative radiology, pathology, and clinical practices

2. Accreditation and Credit Statement
Mayo Clinic College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Mayo Clinic College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

3. DISCLOSURE Conference Directors / Planning Committee
No Relevant Financial Relationship(s)
Thomas M. Habermann, M.D. Rebecca L. King, M.D. Off Label/Investigational Usage
Any off-label or investigational use of a drug of device should be announced to others if discussed.

4. The following are off-label or investigational use and may come up during discussion:
Atezolizumab
Erlotinib
Afatinib
Gefitinib
Osimertinib
Pembrolizumab
Nivolumab
Ipilimumab
Crizotinib
Alectinib
Ceritinib

5. Potential Off-Label or Investigational Drug Use
It is not possible to know/predict
which one of the drugs or which laboratory-based diagnostic tests discussed during this
tumor board are investigational in the individual cases being presented or are being
used in an off-label indication. Any discussed drug or laboratory diagnostic test may be investigational or being utilized as an off-label indication.